- Home
- TTNP vs XYLO Comparison
TTNP vs XYLO Comparison
Compare TTNP & XYLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- XYLO
- Stock Information
- Founded
- TTNP 1991
- XYLO 1999
- Country
- TTNP United States
- XYLO Israel
- Employees
- TTNP N/A
- XYLO N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- XYLO
- Sector
- TTNP Health Care
- XYLO
- Exchange
- TTNP Nasdaq
- XYLO NYSE
- Market Cap
- TTNP 3.0M
- XYLO 3.1M
- IPO Year
- TTNP 1996
- XYLO N/A
- Fundamental
- Price
- TTNP $3.67
- XYLO $3.81
- Analyst Decision
- TTNP
- XYLO
- Analyst Count
- TTNP 0
- XYLO 0
- Target Price
- TTNP N/A
- XYLO N/A
- AVG Volume (30 Days)
- TTNP 25.0K
- XYLO 9.8K
- Earning Date
- TTNP 03-31-2025
- XYLO 09-20-2024
- Dividend Yield
- TTNP N/A
- XYLO N/A
- EPS Growth
- TTNP N/A
- XYLO N/A
- EPS
- TTNP N/A
- XYLO N/A
- Revenue
- TTNP N/A
- XYLO $57,642,000.00
- Revenue This Year
- TTNP N/A
- XYLO $16.76
- Revenue Next Year
- TTNP N/A
- XYLO $5.71
- P/E Ratio
- TTNP N/A
- XYLO N/A
- Revenue Growth
- TTNP N/A
- XYLO N/A
- 52 Week Low
- TTNP $3.03
- XYLO $2.70
- 52 Week High
- TTNP $14.80
- XYLO $8.83
- Technical
- Relative Strength Index (RSI)
- TTNP 50.98
- XYLO 39.04
- Support Level
- TTNP $3.35
- XYLO $4.08
- Resistance Level
- TTNP $4.24
- XYLO $5.33
- Average True Range (ATR)
- TTNP 0.29
- XYLO 0.49
- MACD
- TTNP 0.02
- XYLO -0.09
- Stochastic Oscillator
- TTNP 46.73
- XYLO 0.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About XYLO XYLO TECHNOLOGIES LTD
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in five segments namely, E-Commerce, Online Advertising & Internet Traffic Routing, Online Event Management, Corporate, and others. The company's geographical segments include the United States, Europe, Great Britain, Israel, Canada, Asia, and others.